| Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ... Cancer cell 37 (4), 584-598. e11, 2020 | 138 | 2020 |
| Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, UG Lo, ... Nature cancer 3 (9), 1071-1087, 2022 | 85 | 2022 |
| Acting on identity: Myoblast fusion and the formation of the syncytial muscle fiber S Deng, M Azevedo, M Baylies Seminars in cell & developmental biology 72, 45-55, 2017 | 78 | 2017 |
| The paracrine induction of prostate cancer progression by caveolin-1 CJ Lin, EJ Yun, UG Lo, YL Tai, S Deng, E Hernandez, A Dang, YA Chen, ... Cell death & disease 10 (11), 834, 2019 | 56 | 2019 |
| The formin diaphanous regulates myoblast fusion through actin polymerization and Arp2/3 regulation S Deng, I Bothe, MK Baylies PLoS genetics 11 (8), e1005381, 2015 | 46 | 2015 |
| PI (4, 5) P2 regulates myoblast fusion through Arp2/3 regulator localization at the fusion site I Bothe, S Deng, M Baylies Development 141 (11), 2289-2301, 2014 | 46 | 2014 |
| Leaf surface factors of transgenic Bt cotton associated with the feeding behaviors of cotton aphids: A case study on non-target effects K Xue, S Deng, RJ Wang, FM Yan, CR Xu Science in China Series C: Life Sciences 51 (2), 145-156, 2008 | 37 | 2008 |
| Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer X Li, Y Wang, S Deng, G Zhu, C Wang, NA Johnson, Z Zhang, CR Tirado, ... Cancer cell 41 (8), 1427-1449. e12, 2023 | 28 | 2023 |
| The driver role of JAK‐STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy‐and castration‐resistant prostate cancer UG Lo, YA Chen, J Cen, S Deng, J Luo, H Zhau, L Ho, CH Lai, P Mu, ... Clinical and Translational Medicine 12 (8), e978, 2022 | 27 | 2022 |
| The actin polymerization factor Diaphanous and the actin severing protein Flightless I collaborate to regulate sarcomere size S Deng, RL Silimon, M Balakrishnan, I Bothe, D Juros, DB Soffar, ... Developmental biology 469, 12-25, 2021 | 20 | 2021 |
| Feedback inhibition of ENaC: acute and chronic mechanisms AB Patel, L Yang, S Deng, LG Palmer Channels 8 (5), 444-451, 2014 | 12 | 2014 |
| Diaphanous regulates SCAR complex localization during Drosophila myoblast fusion S Deng, I Bothe, M Baylies Fly 10 (4), 178-186, 2016 | 10 | 2016 |
| UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance C Rodriguez Tirado, C Wang, X Li, S Deng, J Gonzalez, NA Johnson, ... Oncogene 43 (4), 265-280, 2024 | 8 | 2024 |
| ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer Y Xu, Y Yang, Z Wang, M Sjöström, Y Jiang, Y Tang, S Cheng, S Deng, ... Cancer discovery 14 (8), 1496-1521, 2024 | 7 | 2024 |
| MicroRNAs in Prostate Cancer: Small RNAs with Big Roles P Mu, S Deng, X Fan J Clin Cell Immunol, 2015 | 5 | 2015 |
| Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance (vol 3, pg 1071, 2022) S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, U Lo, L Xu, ... NATURE CANCER 3 (10), 1271-1271, 2022 | 3 | 2022 |
| Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, A Mukherji, UG Lo, ... Nature Cancer 3 (10), 1271, 2022 | 3 | 2022 |
| Neuroendocrine differentiation in prostate cancer requires ASCL1 KE Rodarte, S Nir Heyman, L Guo, L Flores, TK Savage, J Villarreal, ... Cancer research 84 (21), 3522-3537, 2024 | 2 | 2024 |
| JAK-STAT Signaling Enables Lineage Plasticity-driven AR Targeted Therapy Resistance S Deng, C Wang, Y Wang, Y Xu, X Li, NA Johnson, UG Lo, L Xu, ... bioRxiv, 2021.11. 02.466956, 2021 | 2 | 2021 |
| Abstract PR004: Exploring the role of ASCL1 in neuroendocrine prostate cancer KE Rodarte, L Flores, V Kandagatla, J Villarreal, TK Savage, S Deng, ... Cancer Research 83 (11_Supplement), PR004-PR004, 2023 | 1 | 2023 |